Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”
Executive Summary
The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin
You may also be interested in...
Now-Mandatory Informed Consent Wording Won't Be Required Retroactively
Study investigators will not have to retroactively "re-consent" clinical trial participants who have not signed on to a soon-to-be-mandatory version of informed consent forms that states that information about the trial will be posted on ClinicalTrials.gov.
Now-Mandatory Informed Consent Wording Won't Be Required Retroactively
Study investigators will not have to retroactively "re-consent" clinical trial participants who have not signed on to a soon-to-be-mandatory version of informed consent forms that states that information about the trial will be posted on ClinicalTrials.gov.
Clinical Trial Certification: Companies Say IND Submissions Should Be Exempt
Several companies say FDA is requiring clinical trial sponsors to submit too much trial information to a new public database, and they particularly oppose certification of investigational new drug submissions